Supernus Pharmaceuticals Files 2024 10-K
Ticker: SUPN · Form: 10-K · Filed: 2025-02-25T00:00:00.000Z
Sentiment: neutral
Topics: 10-K, annual-report, pharmaceuticals
TL;DR
SUPN filed its 2024 10-K. All systems go for pharma giant.
AI Summary
Supernus Pharmaceuticals, Inc. filed its 2024 10-K on February 25, 2025, reporting on its fiscal year ending December 31, 2024. The company, headquartered in Rockville, MD, operates in the pharmaceutical preparations sector. This filing provides a comprehensive overview of its financial performance, business operations, and risk factors for the year.
Why It Matters
This filing is crucial for investors and analysts to understand Supernus Pharmaceuticals' financial health, strategic direction, and potential risks as of the end of the 2024 fiscal year.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Supernus faces inherent risks related to drug development, regulatory approvals, market competition, and intellectual property.
Key Players & Entities
- SUPERNUS PHARMACEUTICALS, INC. (company) — Filer
- 2024-12-31 (date) — Fiscal Year End
- 2025-02-25 (date) — Filing Date
- Rockville, MD (location) — Business Address
- 2834 (industry_code) — Standard Industrial Classification (Pharmaceutical Preparations)
FAQ
What is the primary business of Supernus Pharmaceuticals, Inc.?
Supernus Pharmaceuticals, Inc. is primarily involved in the pharmaceutical preparations industry, as indicated by its SIC code 2834.
When did Supernus Pharmaceuticals, Inc. file its 10-K report for the fiscal year 2024?
The 10-K report for the fiscal year ending December 31, 2024, was filed on February 25, 2025.
Where is Supernus Pharmaceuticals, Inc. headquartered?
Supernus Pharmaceuticals, Inc. is headquartered at 9715 Key West Avenue, Rockville, MD 20850.
What is the SEC file number for Supernus Pharmaceuticals, Inc.?
The SEC file number for Supernus Pharmaceuticals, Inc. is 001-35518.
What is the fiscal year end for Supernus Pharmaceuticals, Inc.?
The fiscal year end for Supernus Pharmaceuticals, Inc. is December 31.
From the Filing
0001356576-25-000017.txt : 20250225 0001356576-25-000017.hdr.sgml : 20250225 20250225161358 ACCESSION NUMBER: 0001356576-25-000017 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 123 CONFORMED PERIOD OF REPORT: 20241231 FILED AS OF DATE: 20250225 DATE AS OF CHANGE: 20250225 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SUPERNUS PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001356576 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35518 FILM NUMBER: 25663368 BUSINESS ADDRESS: STREET 1: 9715 KEY WEST AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 301-838-2500 MAIL ADDRESS: STREET 1: 9715 KEY WEST AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: SUPERNUS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060317 10-K 1 supn-20241231.htm 10-K supn-20241231 0001356576 false 2024 FY http://fasb.org/us-gaap/2024#AccountingStandardsUpdate202006Member P4Y http://fasb.org/us-gaap/2024#BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 http://fasb.org/us-gaap/2024#BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 http://fasb.org/us-gaap/2024#BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 P10Y http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#AccountsPayableAndAccruedLiabilitiesCurrent http://fasb.org/us-gaap/2024#AccountsPayableAndAccruedLiabilitiesCurrent 832 xbrli:shares iso4217:USD iso4217:USD xbrli:shares supn:product supn:segment xbrli:pure supn:right supn:vote supn:installment supn:renewalOption iso4217:EUR 0001356576 2024-01-01 2024-12-31 0001356576 2025-02-18 0001356576 2024-06-30 0001356576 2024-12-31 0001356576 2023-12-31 0001356576 us-gaap:ProductMember 2024-01-01 2024-12-31 0001356576 us-gaap:ProductMember 2023-01-01 2023-12-31 0001356576 us-gaap:ProductMember 2022-01-01 2022-12-31 0001356576 supn:RoyaltyLicenseAndOtherRevenueMember 2024-01-01 2024-12-31 0001356576 supn:RoyaltyLicenseAndOtherRevenueMember 2023-01-01 2023-12-31 0001356576 supn:RoyaltyLicenseAndOtherRevenueMember 2022-01-01 2022-12-31 0001356576 2023-01-01 2023-12-31 0001356576 2022-01-01 2022-12-31 0001356576 us-gaap:CommonStockMember 2021-12-31 0001356576 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001356576 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001356576 us-gaap:RetainedEarningsMember 2021-12-31 0001356576 2021-12-31 0001356576 2021-01-01 2021-12-31 0001356576 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001356576 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2021-12-31 0001356576 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2021-12-31 0001356576 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember us-gaap:CommonStockMember 2021-12-31 0001356576 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001356576 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001356576 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember us-gaap:RetainedEarningsMember 2021-12-31 0001356576 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember 2021-12-31 0001356576 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001356576 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001356576 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001356576 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0001356576 us-gaap:CommonStockMember 2022-12-31 0001356576 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 000